Supernus Pharmaceuticals signed a definitive agreement to acquire fellow biopharmaceutical company Sage Therapeutics for ...

SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.

Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential.

Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus’ leading presence in neuropsychiatric conditions with ...

Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday. These analysts made changes to their price targets on Sage ...

Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...

Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio.

After rejecting a buyout offer from its partner Biogen, the Cambridge firm is being acquired by Supernus Pharmaceuticals.

Supernus Pharmaceuticals agreed to buy Sage Therapeutics for $8.50 a share in cash, equal to a total price of about $561 million at closing.

Supernus Pharmaceuticals (Nasdaq: SUPN) is to buy Sage Therapeutics (Nasdaq: SAGE) for total consideration of around $795 million. Shares in Sage shot up by 35% amid the news by midday Monday, while ...

Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...